| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_86a89d8fa590056286e0bf7f1ae2a3e0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5e5c121269689cbab9b3a4548b15caf3 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7088 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7088
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-00 |
| filingDate |
2018-01-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e39532536710dab79bb2e970e933be8e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ba5427b39a2188c7cd805c13e9490559
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_59d8129e7d5a476902752d2e34e96b80
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_77b921b43d081ab215d65aa73d8242bd |
| publicationDate |
2018-08-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2018139679-A1 |
| titleOfInvention |
Nucleic acid drug capable of inhibiting invasion and metastasis of cancer, and cancer biomarker |
| abstract |
Disclosed is an anti-tumor agent comprising a SNORA23 gene expression inhibitor. The SNORA23 expression inhibitor may be an oligonucleotide containing at least one nucleoside structure represented by formula (1) (wherein each of "Base" and "A" represents a specific substituent or structure) or a pharmacologically acceptable salt thereof. Also disclosed is an anti-tumor agent comprising an SYNE2 gene expression inhibitor. Also disclosed is a use of SNORA23 as a biomarker, said use being characterized in that SNORA23 in a blood sample is measured for the purpose of detecting the occurrence of invasion or metastasis of a tumor. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111440870-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021187540-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019181305-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111440870-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022181807-A1 |
| priorityDate |
2017-01-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |